TY  - BOOK
AU  - Chen, Fang
AU  - Kitabata, Hironori
AU  - Ota, Hideaki
AU  - Pichard, Augusto D
AU  - Satler, Lowell F
AU  - Suddath, William O
AU  - Torguson, Rebecca
AU  - Waksman, Ron
TI  - Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis
SN  - 1878-0938
KW  - *Angioplasty, Balloon, Coronary/ae [Adverse Effects]
KW  - *Coronary Restenosis/th [Therapy]
KW  - *Coronary Stenosis/th [Therapy]
KW  - *Drug-Eluting Stents/ae [Adverse Effects]
KW  - *Everolimus/pd [Pharmacology]
KW  - *Sirolimus/pd [Pharmacology]
KW  - Aged
KW  - Angioplasty, Balloon, Coronary/mt [Methods]
KW  - Cohort Studies
KW  - Confidence Intervals
KW  - Coronary Angiography/mt [Methods]
KW  - Coronary Restenosis/mo [Mortality]
KW  - Coronary Restenosis/ra [Radiography]
KW  - Coronary Stenosis/mo [Mortality]
KW  - Coronary Stenosis/ra [Radiography]
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Patient Safety
KW  - Proportional Hazards Models
KW  - Retreatment
KW  - Retrospective Studies
KW  - Risk Assessment
KW  - Statistics, Nonparametric
KW  - Survival Rate
KW  - Time Factors
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Comparative Study
KW  - Evaluation Studies
KW  - Journal Article
N1  - Available in print through MWHC library: 2002 - present
N2  - BACKGROUND: The optimal treatment for drug-eluting in-stent restenosis remains controversial; CONCLUSIONS: In patients presenting with S-ISR, treatment with implantation of an EES, SES, or POBA is associated with similar clinical outcomes. Patients presenting with recurrent ISR may have a poorer clinical outcome.Copyright � 2015 Elsevier Inc. All rights reserved; METHODS: The study cohort comprised 310 consecutive patients (444 lesions) who presented with S-ISR to our institution and underwent treatment with EES (43 patients), SES (102), or POBA (165). The analyzed clinical parameters were the 1-year rates of death, Q-wave myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), definite stent thrombosis (ST) and major adverse cardiac event (MACE) defined as the composite of death, MI, or TLR at 1-year; OBJECTIVES: The aim of this study was to compare the safety and efficacy of everolimus-eluting stent (EES), sirolimus-eluting stent (SES), and plain old balloon angioplasty (POBA) for the treatment of SES in-stent restenosis (S-ISR); RESULTS: The three groups were well matched for the conventional risk factors for coronary artery disease except for smoking. The 1-year analyzed clinical parameters were similar in the three groups: MACE (EES=14%, SES=18%, POBA=20%; p=0.65), death (EES=2.3%, SES=6.2%, POBA=6.1%; p=0.61), MI (EES=4.8%, SES=2.1%, POBA=2.5%; p=0.69), TLR (EES=11.9%, SES=12.1%, POBA=24%; p=0.78), and TVR (EES=11.9%, SES=24.8%, POBA=22.2%; p=0.23). There were no cases of definite ST. MACE-free rate was significantly lower in patients with recurrent in-stent restenosis (log-rank p=0.006). Presentation with acute MI, number of treated lesions and a previous history of MI were found to be independent predictors of MACE
UR  - http://dx.doi.org/10.1016/j.carrev.2015.01.004
ER  -